Endometriosis ~ Abdominal Pain ~ Endo ~ Scar Tissue ~ Adhesions ~ Infertility ~ Hysterectomy

Monday, April 09, 2007

Growth-associated protein 43-positive sensory nerve fibers accompanied by immature vessels are located in or near peritoneal endometriotic lesions.

Mechsner S,
Schwarz J,
Thode J,
Loddenkemper C,
Salomon DS,
Ebert AD.
Endometriosis Research Center Berlin, Department of Gynecology.
OBJECTIVE: To investigate the topographical relationship between nerve fibers and peritoneal endometriotic lesions and to determine the origin of endometriosis-associated nerve fibers. DESIGN: Retrospective nonrandomized study. SETTING: University hospital endometriosis research center. PATIENT(S): Premenopausal women with histologically confirmed endometriosis were selected (n = 73). Peritoneal endometriotic lesions (n = 106) and unaffected peritoneal biopsies from patients without endometriosis (n = 9) were obtained. INTERVENTION(S): Immunohistochemistry was used to study the expression of neurofilament, substance P, smooth muscle actin, von Willebrand factor, growth-associated protein 43, nerve growth factor, and neutrophin-3 in peritoneal endometriotic lesion samples from women with symptomatic endometriosis and in peritoneal samples from women without endometriosis. RESULT(S): Pain-conducting substance-P-positive nerve fibers were found to be directly colocalized with human peritoneal endometriotic lesions in 74.5% of all cases. The endometriosis-associated nerve fibers are accompanied by immature blood vessels within the stroma. Nerve growth factor and neutrophin-3 are expressed by endometriotic cells. Growth-associated protein 43, a marker of neural outgrowth and regeneration, is expressed in endometriosis-associated nerve fibers but not in existing peritoneal nerves. CONCLUSION(S): The data provide the first evidence of direct contact between sensory nerve fibers and peritoneal endometriotic lesions. This implies that the fibers play an important role in the etiology of endometriosis-associated pelvic pain. Moreover, emerging evidence suggests that peritoneal endometriotic cells exhibit neurotrophic properties.
PMID: 17412328 [PubMed - as supplied by publisher]
Source

Wednesday, April 04, 2007

'Lung Endometriosis is Life Threatening and can be Fatal,' Says Glynis Wallace, DMD, Author, Living with Lung and Colon Endometriosis

Download this press release as an Adobe PDF document.
The truth about Lung Endometriosis is incontrovertible -- malice may attack it, ignorance may deride it, but in the end, you are forced to face it. This non-cancerous disease, lung endometriosis, can be fatal. You can die from lung endometriosis. Does this sound alarming? It should. In the misinformation aftermath of last month's National Endometriosis Awareness month observation, it is now supremely evident that the message about the perils of endometriosis is vastly understated, according to Glynis Wallace, DMD, author of the globally acclaimed book Living With Lung and Colon Endometriosis: Catamenial Pneumothorax, and the founder of the new website www.catamenialpneumothorax.org.
Torrance, CA (PRWeb) April 4, 2007 -- You can die from lung endometriosis. Does this sound alarming? It should.
In the misinformation aftermath of last month's National Endometriosis Awareness month observation, it is now supremely evident that the message about the perils of endometriosis is vastly understated, according to Glynis Wallace, DMD, author of the globally acclaimed book Living With Lung and Colon Endometriosis: Catamenial Pneumothorax, and the founder of the new website www.catamenialpneumothorax.org. This life threatening and devastating disease is finally receiving worldwide recognition among physicians and its victims.
Explains Dr. Wallace, "Morbidity and mortality is a little known result of endometriosis that causes the lung(s) to collapse (also known as Catamenial Hemopneumothorax and Catamenial Pneumothorax). There is misinformation or a misnomer in the world of endometriosis that you cannot die from endometriosis. This information is incorrect."
How can this be fatal?
Lung endometriosis resulting in Catamenial Hemopneumothorax and Catamenial Pneumothorax causes the inability to breathe. Says Dr. Wallace, "We need oxygen to keep us alive, when breathing stops, the heart soon stops beating, brain damage occurs leading to irreversible consequences."
Her personal quest to manage her own battle with lung endometriosis underscores the severity of the symptoms.
Recounts Dr. Wallace, "My last catamenial pneumothorax started with 'shortness of breath' leading to the seventh chest tube placement, a tension pneumothorax and decompression of my chest.
Dr. Wallace, a former USAF Major and a graduate of Tufts University School of Dental Medicine, explains that diagnosing endometriosis early is an important first step in helping "prevent" endometriosis sufferers from experiencing a life of monthly pain, discomfort and even some life threatening symptoms.
"Living with Lung and Colon Endometriosis: Catamenial Pneumothorax," outlines Dr. Wallace's 13-year experience with pulmonary endometriosis through narrative summaries from the physicians who attempted to control this disease. As an active duty military officer, she underwent extensive and extremely thorough diagnostic tests to determine fitness for duty. This led to excellent medical treatment, which allowed her to continue serving on active duty.
Endometriosis is an abnormal growth of tissue in the pelvic area and can travel through the body attaching to organs in its path. It has many undefined symptomatic presentations. The symptoms may include back pain, chest pain, shortness of breath, pressure, bloating, constipation, seizures, fatigue and consistently painful menstrual cramps.
View Endometriosis Migration Organ Documentation blog at http://blog.catamenialpneumothorax.org. Dr. Wallace recently launched the website www.catamenialpneumothorax.org to spearhead quicker, easier and more widespread global diagnosis, and subsequent treatment regimes.
For media inquiries, please contact Peggy C. Frank, MBA, Frank Public Relations Worldwide, 818-735-3591, pfrank @ frankpr.com, www.frankpr.com.
http://www.emediawire.com/releases/2007/4/emw516304.htm

Tuesday, April 03, 2007

Hope for Ending the Pain, Infertility of Endometriosis?

Description An ongoing U-M Health System study is looking at the use of a common diabetes medication, rosiglitzaone, to treat endometriosis.
Use of the drug would allow women with endometriosis to be treated without compromising their future fertility.
Video is available by contacting the source.
Newswise — Jan Ruma’s pain was getting worse, but she wrote it off as just a part of growing older and a normal side-effect of “that time of the month.”
“I was increasingly having painful menstrual periods, cramping, painful abdomen and lower back pain,” says Ruma, 43.
After running some tests, her doctor discovered that Ruma had endometriosis, a painful condition that affects one in 10 women, usually of childbearing age. In addition to painful menstrual periods, it can cause fertility problems, heavy bleeding, painful intercourse and appears to be associated with autoimmune disorders such as rheumatoid arthritis, lupus and thyroid disorders.
“Endometriosis, simply put, is when the lining of the uterus, or the womb, is located where it should not be: outside of the uterus,” says Dan Lebovic, M.D., M.A., assistant professor of obstetrics and gynecology at the University of Michigan Medical School, who is exploring new treatment options for women with endometriosis.
“The quality of life in patients with endometriosis is severely compromised. We see a lot of patients whose jobs have been jeopardized because they have to stay home on account of pain, sometimes up to two weeks at a time,” he notes.
Treatments for the condition include medications and surgery, says Lebovic, also the co-director of the U-M Health System Endometriosis Center. Physicians sometimes prescribe pain killers or oral contraceptives to diminish the woman’s period and therefore reduce her pain, and hormones that suppress ovarian function and therefore suppress the estrogen that “seems to feed these lesions,” he says.
Surgical options include a simple laparoscopy, a procedure with only small incisions that can be used to excise small lesions in cases of mild endometriosis. More severe cases may require a laparotomy, a surgery with a larger incision in the abdomen that may require many weeks to months of recovery time. Women who do not wish to maintain their fertility occasionally resort to a hysterectomy, the full removal of the uterus and ovaries.
None of these options is perfect, Lebovic notes. In many cases, the treatment of the pain and heavy periods can lead to the end of a woman’s fertility. That’s why Lebovic and other U-M Health System researchers are exploring the possible use of the diabetes medication called rosiglitazone as a treatment for endometriosis.
The trial is in progress of recruiting participants with Stage I or II (minimal or mild) endometriosis, and there is no conclusive result yet, but Lebovic says the medication may help to decrease endometriosis patients’ pain and lesion size without making them infertile. “We are certainly hopeful this medicine will make a great impact on women with endometriosis,” Lebovic says.
Ruma is one of the participants in the trial. While it is too early to say definitively how the treatment will affect her, she says it has improved her health and reduced her symptoms in the six months she has been on the medication.
7 things to know about endometriosis
1.What it is: Endometriosis is a condition in which the lining of the uterus is located outside of the uterus.
2. Symptoms: Painful periods, heavy bleeding, painful intercourse and sometimes fertility problems. Some women also have chronic pain in the lower back and pelvis, as well as intestinal pain.
3. Diagnosis: A doctor will begin with a physical exam, including a pelvic exam, followed by ultrasound and/or magnetic resonance imaging (MRI). The only way to be certain that a person has endometriosis is through a surgery called laparoscopy, in which a small, lighted tube is used to see the uterus region.
4.Prevention: Endometriosis cannot be prevented.
5. Who is at risk: One in 10 women has endometriosis. Typically it occurs when a women is of childbearing age. Women have a five- or six-times greater chance of developing endometriosis if a family member has had it, and women who started their periods early may have a higher risk.
6. Treatment: Treatments can assist with the pain and fertility issues that arise with endometriosis. Pain medication, birth control pills or oral contraceptives, hormone therapy to suppress ovarian function, and surgery are some options. Several types of surgery can be performed, including laparoscopy (surgery with small incisions used to remove small lesions), laparotomy (a major abdominal surgery with a larger incision) or hysterectomy (removal of the uterus). There is no cure for endometriosis.
7. Possible treatment in the future: University of Michigan Health System researchers are conducting a clinical trial involving a medication called rosiglitazone, currently used to treat people with diabetes. To learn more about this study, visit http://www.umengage.org.
For more information, visit these Web sites:
University of Michigan Endometriosis Center http://www2.med.umich.edu/departments/obgyn/index.cfm?fuseaction=Obgyn.UMEC
U-M Adult Health Advisor: What is Endometriosis? http://www.med.umich.edu/1libr/aha/aha_endometr_crs.htm
Womenshealth.gov: Endometriosishttp://www.4woman.gov/faq/endomet.htm
American College of Obstetricians and Gynecologistshttp://www.acog.org/publications/patient_education/bp013.cfm
Source

Community Health Network Lands Embryo Adoption Program

InsideIndianaBusiness.com Report

3/30/2007 12:13:02 PM
Indianapolis-based Community Health Network has become the first national satellite location for an embryo adoption program. The program offers a new option for infertile couples and is in affiliation with the National Embryo Donation Center. Under the program, embryos left over from consenting families that have tried invitro fertilization are placed for adoption and implanted in an infertile woman. In the past, these embryos have been thrown out or donated to research.
Press ReleaseIndianapolis, IN---Community Health Network has been chosen as a national site for an embryo adoption program in affiliation with the National Embryo Donation Center (NEDC) in Knoxville, Tennessee. This unique program offers a new option for infertile couples. Community is a national leader in the cryopreservation of eggs.In the embryo adoption process, an infertile couple receives donated embryos (fertilized eggs) from a couple who have completed their families using invitro fertilization (IVF). When couples undergo IVF, there are often leftover embryos that are frozen and stored for later use. In the past, frozen embryos have been discarded or donated to research. Women who choose embryo adoption as an answer to infertility will experience pregnancy, labor and delivery if the embryo transfer is successful. “We are honored to be chosen as a partner with the NEDC,” said Dr. Donald Cline, reproductive endocrinologist/fertility specialist with Reproductive Endocrinology Associates. “This is an exciting new option for women who wish to conceive. When the genetic parents decide their family is complete and embryos are still frozen, they usually face a moral or ethical dilemma about what to do with the leftover embryos. The embryo adoption program offers an acceptable answer to many of these couples.”“We are happy to be able to add embryo adoption to the list of advanced reproductive technologies offered in our program,” said Dr. Jeffrey Boldt, scientific and program director for Assisted Fertility Services at Community Hospital North and a longtime partner of Dr. Cline. “Our goal is to provide patients with a range of options to build their families.”The adoption process is similar to that of the traditional adoption of children. The NEDC undertakes an extensive screening of potential couples wanting to donate their embryos, including the medical, legal and social requirements of embryo donation. Recipient couples also undergo extensive screening. Surveys estimate that only 9,000 of the 400,000 embryos currently in cryopreservation (freezing) in the U.S. are available for adoption to another couple. Since most of those embryos will likely not be transferred to the genetic mother, they are either stored for an indefinite period of time, or thawed and discarded. The pregnancy rate is approximately 40-percent per embryo transfer.For more information on embryo adoption, visit www.reproductivehope.com or www.eCommunity.com. The Web site for the National Embryo Donation Center is www.embryodonation.org. The NEDC is a non-profit organization endorsed by the Christian Medical Association.

Monday, April 02, 2007

UK Fertility Watchdog Considers Reducing Multiple Embryo Implants

Written by Catharine Paddock
The UK's fertility watchdog, the Human Fertilisation and Embryology Authority (HFEA), is to consider reducing the number of embryos that can be implanted in women having IVF treatment in order to bring down the rate of multiple births...[read article]

European Parliament host seminar to highlight suffering of women with endometriosis

This week Diana Wallis MEP, Vice-President of the European Parliament, will host a seminar in Brussels to highlight the campaign to raise awareness of endometriosis. Diana Wallis MEP said: "Raising awareness of this disease is essential as endometriosis affects at least 14 million women and girls in the EU. "Although it is difficult to predict precisely how much endometriosis costs, it is thought that in the region of €30 billion a year is lost just in days taken off work due to illness. Yet due to a lack of awareness, both in the medical professions and amongst the general public, sufferers face an average wait of eight years from presenting with symptoms to being diagnosed." As part of this awareness-raising exercise Diana Wallis MEP, herself an endometriosis sufferer, will host a lunch seminar on 28 March at 12.30 in the European Parliament.
She will be joined by Senator Laura Bianconi, who will explain the Italian five-year plan to improve treatments for those with endometriosis. Italy is the first member state to recognise endometriosis as a social disease and Senator Bianconi will call on her colleagues across Europe to do the same. Diana Wallis MEP further added: "Recent studies show that endometriosis costs society more than migraine and Crohn's disease. However researchers suffer from a lack of funding. I am hoping we really raise awareness and turn this around with the event this week." In 2005 a Written Declaration on Endometriosis, organised by Diana Wallis in the European Parliament, attracted more signatures than on any other human health issue. Lone Hummelshoj, Secretary General of the World Endometriosis Society, concluded: “Despite the success of the 2005 Written Declaration, endometriosis is still being left behind. At a time where gender equality appears to be a priority, women’s health and endometriosis in particular – in contrast with diseases such as osteoarthritis – is being neglected despite its prevalence and impact on society. It is time we start seeing investment into female specific benign, chronic diseases on the same scale as for male specific benign and chronic disease.”
Please visit the World Endometriosis Society website
http://wes.endometriosis.org/

ESHRE guideline for the diagnosis and treatment of endometriosis

The aim of this guideline is to provide clinicians with up-to-date information about the diagnosis and treatment of endometriosis, based upon the best available evidence. This guideline, which is reviewed annually, was last updated on 17 June 2006.
ObjectiveThe objective was to develop recommendations for the diagnosis and treatment of endometriosis and its associated symptoms.
DesignA working group was convened comprised of practising gynaecologists and experts in evidence-based medicine from Europe, as well as an endometriosis self-help group representative.
After reviewing exisiting evidence-based guidelines and systematic reviews, the expert panel met on three occasions for a day during which the guideline was developed and refined. Recommendations based soley on the clinical experience of the panel were avoided as much as possible. The entire ESHRE Special Interest Group for endometriosis and endometrium was given the opportunity to comment on the draft guideline, after which it was available for comment on the ESHRE website for 3 months. The working group then ratified the guideline by unanimous or near-unanimous voting; finally, it was approved by the ESHRE Executive Committee.
The guideline will be updated annually, and has been made available on this website with hyperlinks to the supporting evidence, and the relevant references and abstracts.
Main conclusionsFor women presenting with symptoms suggestive of endometriosis, a definitive diagnosis of most forms of endometriosis requires visual inspection of the pelvis at laparoscopy as the 'gold standard' investigation. However, pain symptoms suggestive of the disease can be treated without a definitive diagnosis using a therapeutic trial of a hormonal drug to reduce menstrual flow.
In women with laparoscopically confirmed disease, suppression of ovarian function for 6-months reduces endometriosis-associated pain; all hormonal drugs studied are equally effective although their side-effects and cost profiles differ. Ablation of endometriotic lesions reduces endometriosis-associated pain and the smallest effect is seen in patients with minimal disease; there is no evidence that also performing laparoscopic uterine nerve ablation (LUNA) is necessary.
In minimal-mild endometriosis, suppression of ovarian function to improve fertility is not effective, but ablation of endometriotic lesions plus adhesiolysis is effective compared to diagnostic laparoscopy alone. There is insufficient evidence available to determine whether surgical excision of moderate-severe endometriosis enhances pregnancy rates. IVF is appropriate treatment especially if there are coexisting causes of infertility and/or other treatments have failed, but IVF pregnancy rates are lower in women with endometriosis than in those with tubal infertility.
The management of severe/deeply infiltrating endometriosis is complex and referral to a centre with the necessary expertise is strongly recommended. Patient self-help groups can provide invaluable counselling, support and advice.
The guideline has been produced by the ESHRE Special Interest Group for Endometriosis and Endometriosis Guideline Development Group, and the original, concise, version was published in Human Reproduction 2005;20(10):2698-2704
This website provides access to the concise version of this guideline and to further supporting documentation. To access the concise version of this guideline please click on the 'Concise' link under each chapter heading. To access the supporting documentation for this guideline please click on the 'Supporting Documentation' link under each chapter heading.